Histological Evaluation of Products of Conception, Who Benefits From It?

Histological Evaluation of Products of Conception, Who Benefits From It? Publisher Pubmed

Soltanghoraee H¹ ; Mohazzab A^{2, 3} ; Soltani A⁴ ; Ansaripour S¹ ; Tavakoli M¹ ; Rafati M¹ ; Zarnani AH⁵ ; Ghaffari SR¹

Source: Fetal and Pediatric Pathology Published:2023

Abstract

Background: Histopathological evaluation of the first trimester pregnancy loss has always been controversial. Although it is recommended, it is not a part of guidelines. Methods: Six hundred eighty-six samples in a referral infertility clinic were evaluated microscopically and categorized. Two hundred ninety-five cases were evaluated by genetic methods (Multiplex Ligation-dependent Probe Amplification). Results: From 569 samples with chorionic villi, 361 cases had history of three or more abortions. 18.3% of this group showed chronic intervillous of unknown etiology (CIUE) and 8.3% revealed intervilli fibrin deposition, both pathologies with a high risk of recurrence. History of a live child was significantly higher in CIUE group. 29% of genetically evaluated cases had a chromosomal abnormality. Conclusion: Histological evaluation of recurrent pregnancy loss could illuminate the cause of abortion in relatively acceptable percentage of cases, especially in mothers with higher number of previous abortion, mothers with a history of live child and in referral centers. © 2022 Taylor & Francis Group, LLC.

Related Docs

View other Related Docs

1. Factors Predicting a Positive Pregnancy Screening Test at First Trimester, Tehran University Medical Journal (2021)

2. Performance of Cell Free Dna As a Screening Tool Based on the Results of First Trimester Screening, Molecular Cytogenetics (2024)

3. Association of Cell-Free Fetal Dna at 11-17 Weeks of Pregnancy and the Outcome of Pregnancy, International Journal of Women's Health and Reproduction Sciences (2023)

Experts (# of related papers)

View all Related Experts

Mohammad Hossein Modarressi (1)

Azadeh Tarafdari Manshadi (1)

Style	Citing Format
MLA	Soltanghoraee H, et al.. "Histological Evaluation of Products of Conception, Who Benefits From It?." Fetal and Pediatric Pathology, vol. 42, no. 1, 2023, pp. 30-43.
APA	Soltanghoraee H, Mohazzab A, Soltani A, Ansaripour S, Tavakoli M, Rafati M, Zarnani AH, Ghaffari SR (2023). Histological Evaluation of Products of Conception, Who Benefits From It?. Fetal and Pediatric Pathology, 42(1), 30-43.
Chicago	Soltanghoraee H, Mohazzab A, Soltani A, Ansaripour S, Tavakoli M, Rafati M, Zarnani AH, Ghaffari SR. "Histological Evaluation of Products of Conception, Who Benefits From It?." Fetal and Pediatric Pathology 42, no. 1 (2023): 30-43.
Harvard	Soltanghoraee H et al. (2023) 'Histological Evaluation of Products of Conception, Who Benefits From It?', Fetal and Pediatric Pathology, 42(1), pp. 30-43.
Vancouver	Soltanghoraee H, Mohazzab A, Soltani A, Ansaripour S, Tavakoli M, Rafati M, et al.. Histological Evaluation of Products of Conception, Who Benefits From It?. Fetal and Pediatric Pathology. 2023;42(1):30-43.
BibTex	@article{ author = {Soltanghoraee H and Mohazzab A and Soltani A and Ansaripour S and Tavakoli M and Rafati M and Zarnani AH and Ghaffari SR}, title = {Histological Evaluation of Products of Conception, Who Benefits From It?}, journal = {Fetal and Pediatric Pathology}, volume = {42}, number = {1}, pages = {30-43}, year = {2023} }
RIS	TY - JOUR AU - Soltanghoraee H AU - Mohazzab A AU - Soltani A AU - Ansaripour S AU - Tavakoli M AU - Rafati M AU - Zarnani AH AU - Ghaffari SR TI - Histological Evaluation of Products of Conception, Who Benefits From It? JO - Fetal and Pediatric Pathology VL - 42 IS - 1 SP - 30 EP - 43 PY - 2023 ER -

Science Communicator Platform

Authors

Abstract